Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)

Ovid Therapeutics filings provide 1 years of Non-Current Deffered Revenue readings, the most recent being $10.2 million for Q4 2020.

  • Quarterly Non-Current Deffered Revenue changed N/A to $10.2 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2020, changed N/A year-over-year, with the annual reading at $10.2 million for FY2020, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $10.2 million in Q4 2020 for Ovid Therapeutics, up from $9.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.2 million in Q4 2020 and bottomed at $9.9 million in Q3 2020.